2YR企业会员
| 英文名称 | 中文名称 | CAS |
|---|---|---|
| TGX-221 | (+/-)-7-甲基-2-(吗啉-4-基)-9-(1-苯基氨基乙基)吡啶并[1,2-A]嘧啶-4-酮 | 663619-89-4 |
| PHA-767491(HCl) | PHA767491 | 845714-00-3 |
| Ganetespib | GANETESPIB | 888216-25-9 |
| Moclobemide (Ro 111163) | 吗氯贝胺 | 71320-77-9 |
| Ulocuplumab | Ulocuplumab | 1375830-34-4 |
| Brontictuzumab | Brontictuzumab | 1447814-75-6 |
| Research Grade Obexelimab | 奥贝利单抗 | 1690307-05-1 |
| Vandortuzumab Vedotin | Vandortuzumab Vedotin | 1471985-92-8 |
| Amivantamab | AMIVANTAMAB (埃万妥单抗 ) | 2171511-58-1 |
| GSK 429286A | N-(6-氟-1H-吲唑-5-基)-2-甲基-6-氧代-4-[4-(三氟甲基)苯基]-1,4,5,6-四氢-3-吡啶甲酰胺 | 864082-47-3 |
| Sparsentan | 4'-[(2-丁基-4-氧代-1,3-二氮杂螺[4.4]壬-1-烯-3-基)甲基]-N-(4,5-二甲基-3-异恶唑基)-2'-(乙氧基甲基)-[1,1'-联苯]-2-磺酰胺 | 254740-64-2 |
| VR23 | VR23 | 1624602-30-7 |
| Anetumab Ravtansine | Anetumab Ravtansine | 1375258-01-7 |
| Fletikumab | 夫来库单抗 | 1357158-22-5 |
| Abituzumab | Abituzumab | 1105038-73-0 |
| Lenzilumab | Lenzilumab | 1229575-09-0 |
| Research Grade Tafasitamab | TAFASITAMAB (ANTI-CD19) | 1422527-84-1 |
| CID 755673 | 2,3,4,5-Tetrahydro-7-hydroxy-1H-benzofuro[2,3-c]azepin-1-one | 521937-07-5 |
| HMN-214 | (E)-4-[2-[2-[N-乙酰基-N-[(4-甲氧基苯基)磺酰]氨基]苯基]乙烯基]吡啶 1-氧化物 | 173529-46-9 |
| LMK-235 | N-[[6-(羟基氨基)-6-氧代己基]氧基]-3,5-二甲基-苯甲酰胺 | 1418033-25-6 |
| SB 366791 | 3-(4-氯苯基)-N-(3-甲氧基苯基)-2-丙烯酰胺 | 472981-92-3 |
| Tirzepatide | 替尔泊肽 | 2023788-19-2 |
| Tarextumab | Tarextumab | 1359940-55-8 |
| Anifrolumab | Anifrolumab | 1326232-46-5 |
| Emibetuzumab | Emibetuzumab | 1365287-97-3 |
| Lumretuzumab | Lumretuzumab | 1448327-63-6 |
| SKF38393 HCl | SKF38393 HCL | 62717-42-4 |
| Eldelumab | Eldelumab | 946414-98-8 |
| Ralpancizumab | Ralpancizumab | 1407495-04-8 |
| Denintuzumab Mafodotin | Denintuzumab Mafodotin | 1399672-02-6 |
| Lacutamab | LACUTAMAB (拉可妥单抗 ) | 2187368-16-5 |
| semaglutide | 司美格鲁肽 | 99291-20-0 |
| GW0742 | GW0742 | 317318-84-6 |
| A66 | A66 | 1166227-08-2 |
| Apoptozole | BenzaMide, 4-[[2-[3,5-bis(trifluoroMethyl)phenyl]-4,5-bis(4-Methoxyphenyl)-1H-iMidazol-1-yl]Methyl]- | 1054543-47-3 |
| APS-2-79 | APS-2-79 盐酸盐 | 2002381-31-7 |
| mu-conotoxin | 芋螺肽 | 936616-33-0 |
| AG 490 | 酪氨酸磷酸化抑制剂AG 490 | 133550-30-8 |
| Dapirolizumab Pegol | Dapirolizumab Pegol | 1416147-64-2 |
| Coltuximab Ravtansine | Coltuximab Ravtansine | 1269764-99-9 |
| Firivumab | Firivumab | 1443004-15-6 |
| Lokivetmab | Lokivetmab | 1533403-95-0 |
| Kartogenin | 2-([1,1-联苯]-4-基氨基甲酰)苯甲酸 | 4727-31-5 |
| Oprozomib;ONX-0912 | ONX0912 | 935888-69-0 |
| FPS-ZM1 | N-BENZYL-4-CHLORO-N-CYCLOHEXYLBENZAMIDE | 945714-67-0 |
| KC7F2 | KC7F2 | 927822-86-4 |
| HLCL-61 | HLCL-61 盐酸盐 | 1158279-20-9 |
| Avelumab | 阿维鲁单抗 | 1537032-82-8 |
| Reversine | REVERSINE | 656820-32-5 |
| Scriptaid | SCRIPTAID | 287383-59-9 |
| Tovetumab | Tovetumab | 1243266-04-7 |
| Enfortumab Vedotin | 维汀-恩弗妥单抗 | 1346452-25-2 |
| Pasotuxizumab | Pasotuxizumab | 1442657-12-6 |
| Begelomab | Begelomab | 1403744-56-8 |
| BLU-945 | BLU-945 | 2660250-10-0 |
| SW-033291 | SW033291 | 459147-39-8 |
| Daprodustat;GSK1278863 | 达普司他 | 960539-70-2 |
| Idarucizumab | Idarucizumab | 1362509-93-0 |
| Aducanumab | 阿杜那单抗 | 1384260-65-4 |
| Bimekizumab | BIMEKIZUMAB | 1418205-77-2 |
| Guselkumab | 古塞库单抗 | 1350289-85-8 |
| Tosatoxumab | Tosatoxumab | 1374419-41-6 |
| Bococizumab | Bococizumab | 1407495-02-6 |
| Vanucizumab | Vanucizumab | 1448221-05-3 |
| Vitamin K2 (Mk7) | 维生素K2 MK7 | 2124-57-4 |
| GW2580 | GW2580 | 870483-87-7 |
| Vidofludimus;4SC-101 | 维多氟拉迪莫 | 717824-30-1 |
| Stattic | Stattic | 19983-44-9 |
| AZD9496 | (E)-3-[3,5-二氟-4-[(1R,3R)-2-(2-氟-2-甲基丙基)-3-甲基-2,3,4,9-四氢-1H-吡啶并[3,4-B]吲哚-1-基]苯基]丙烯酸 | 1639042-08-2 |
| ON123300 | 8-环戊基-7,8-二氢-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-7-氧代-吡啶并[2,3-D]嘧啶-6-甲腈 | 1357470-29-1 |
| CC122 | 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4H)-基)哌啶-2,6-二酮 | 1015474-32-4 |
| BMS-986165 | BMS-986165 | 1609392-27-9 |
| Otlertuzumab | Otlertuzumab | 1372645-37-8 |
| Go 6983 | 3-[1-[3-(二甲基氨基)丙基]-5-甲氧基-1H-吲哚-3-基]-4-(1H-吲哚-3-基)-1H-吡咯-2,5-二酮 | 133053-19-7 |
| Sofituzumab Vedotin | Sofituzumab Vedotin | 1418200-58-4 |
| Ontuxizumab | Ontuxizumab | 946415-62-9 |
| Remtolumab | 壬托鲁单抗 | 1791410-27-9 |
| Evinacumab | Evinacumab | 1446419-85-7 |
| 3-Piperidinecarboxamide, N-(4,6-difluoro-2-benzothiazolyl)-1-[2-(dimethylamino)ethyl]- | 化合物MCUF-651 | 2747162-85-0 |
| WP 1066 | (2E)-3-(6-溴-2-吡啶基)-2-氰基-N-[(1S)-1-苯基乙基]-2-丙烯酰胺 | 857064-38-1 |
| BAY-57-1293;Pritelivir | 普瑞利韦 | 348086-71-5 |
| Tazemetostat (EPZ-6438) | EPZ-6438 | 1403254-99-8 |
| BLU-9931 | BLU 9931 | 1538604-68-0 |
| Durvalumab | 德瓦鲁单抗 | 1428935-60-7 |
| Atezolizumab | 阿特珠单抗 | 1380723-44-3 |
| Varlilumab | 伐立鲁单抗 | 1393344-72-3 |
| dinutuximab | dinutuximab | 1363687-32-4 |
| UCB-9260 | UCB-9260 | 1515888-53-5 |
| Vantictumab | 万替妥单抗 | 1345009-45-1 |
| Lifastuzumab Vedotin | Lifastuzumab Vedotin | 1401812-88-1 |
| Lulizumab Pegol | Lulizumab Pegol | 1421830-13-8 |
| Imalumab | Imalumab | 1430205-07-4 |
| PD 123319 ditrifluoroacetate | PD 123319 二(三氟乙酸盐) | 136676-91-0 |
| SB 742457 | 3-苯基磺酰基-8-(哌嗪-1-基)喹啉 | 607742-69-8 |
| SH-4-54 | SH-4-54 | 1456632-40-8 |
| Vobarilizumab | Vobarilizumab | 1628814-88-9 |
| Codrituzumab | 考曲妥珠单抗 | 1365267-33-9 |
| Margetuximab | 玛格妥昔单抗 | 1350624-75-7 |
| Abrilumab | 阿利鲁单抗 | 1342290-43-0 |
| Emactuzumab | Emactuzumab | 1448221-67-7 |
联系方式
